TRIP13 overexpression is also associated with chemotherapy resistance, promotes the progression of head and neck cancer, breast cancer, and colorectal cancer, and is significantly associated with poor prognosis in patients (Banerjee et al., 2014; Wang et al., 2014; Sheng et al., 2018). Here, TRIP13 is linked to head and neck cancer.